Idelalisib (CAL-101, GS-1101)

For research use only.

Catalog No.S2226

205 publications

Idelalisib (CAL-101, GS-1101) Chemical Structure

CAS No. 870281-82-6

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.

Selleck's Idelalisib (CAL-101, GS-1101) has been cited by 205 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
Targets
p110δ [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
2.5 nM 89 nM
In vitro

CAL-101 is not sensitive to other PI3K class I subunits including p110α, p110β, and p110γ. CAL-101 specifically blocks FcϵR1 p110δ-mediated CD63 expression with an EC50 of 8 nM in primary basophil. CAL-101 exhibits greater activity in B-cell acute lymphoblastic leukemia (B-ALL) and chronic lymphocytic leukemia (CLL) cells compared with acute myeloid leukemia (AML) and myeloproliferative neoplasm (MPN) cells. CAL-101 produces the reduction in pAktS473, pAktT308, and the downstream target S6 in SU-DHL-5, KARPAS-422 and CCRF-SB cells with EC50 of 0.1 to 1.0 μM. [1] CAL-101 induces selective cytotoxicity in CLL cells independent of IgVH mutational status or interphase cytogenetics, primarily through a caspase-dependent mechanism. CAL-101 induces cytotoxicity preferentially to CLL cells compared with normal B cells, without producing cytotoxicity in other hematopoietic cells, compared to LY294002. CAL-101 lacks direct cytotoxic potential to T cells and nature killer (NK) cells. CAL-101 can inhibit production of inflammatory cytokines, such as IL-6, IL-10, TNF-α, and IFN-γ, and activation-induced cytokines, such as CD40L. CAL-101 also antagonizes CD40L-mediated CLL cell survival. [2] CAL-101 induces an accumulation of cells in G1 and a decrease in the S-phase population in L1236 and L591 cells, which indicates CAL-101 as a novel strategy for the treatment of hodgkin lymphoma (HL). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MEC1 NInQOI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPmd4FETE2VTx?= NWj3[I1OUUN3ME2yNE41KM7:TR?= NE\VZpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm5PVM2Oid-MkW5PVk{PTJ:L3G+
CLL PBMCs MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPGSG1UVw>? MYXJR|UxRTJwOTDuUS=> NXjxOmlGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5NVczPjdpPkK1PVE4OjZ5PD;hQi=>
U266 M2fYXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7Db4RSPDBizszN NHvOZ5M1QCCq MoCxO|kvPSViaX7obYJqfGmxbjDyZZRm NVvVUYlERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN|k{OzJpPkK1N|M6OzN{PD;hQi=>
K562 NFLsOFZHfW6ldHnvckBCe3OjeR?= M1PZUVEh|ryP MkWyN{Bp MU\Jcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25? NIT1eos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCxOFc4PSd-MkWwNVQ4PzV:L3G+
K562 MVvGeY5kfGmxbjDBd5NigQ>? NWrmR|VROSEQvF2= MlXMN{Bp NFvERYFKdmirYnn0bY9vKG:oIGC3NHM3UyCyaH;zdIhwenmuYYTpc44> NXHxOId5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNVQ4PzVpPkK1NFE1Pzd3PD;hQi=>
K562 MYDGeY5kfGmxbjDBd5NigQ>? NHvD[XoyKM7:TR?= NUDY[pRYOyCq MUjJcohq[mm2aX;uJI9nKEeVS{OgdIhwe3Cqb4L5cIF1cW:w NV\ObmZqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNVQ4PzVpPkK1NFE1Pzd3PD;hQi=>
K562 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHRNUDPxE1? NVTETIpvPzJiaB?= NFzZU2JKdmirYnn0bY9vKG:oIIDyc4xq\mW{YYTpc44> M4LXU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEG0O|c2Lz5{NUCxOFc4PTxxYU6=
Primary AML cell M1f2U2Z2dmO2aX;uJGF{e2G7 Mn7aNUDPxE1? NE[xb5U{KGh? MV7Jcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25? MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTBzNEe3OUc,OjVyMUS3O|U9N2F-
Primary AML cell MmjYSpVv[3Srb36gRZN{[Xl? NGTvNW0yKM7:TR?= NYLCW2lLOyCq NITWRZdKdmirYnn0bY9vKG:oIGC3NHM3UyCyaH;zdIhwenmuYYTpc44> M2PYcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEG0O|c2Lz5{NUCxOFc4PTxxYU6=
Primary AML cell NWX6c25pTnWwY4Tpc44hSXO|YYm= M4Lt[|Eh|ryP NVOxfGVTOyCq Mn\aTY5pcWKrdHnvckBw\iCJU1uzJJBpd3OyaH;yfYxifGmxbh?= M{O0c|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEG0O|c2Lz5{NUCxOFc4PTxxYU6=
Primary AML cell NVPSSo5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jaNFEh|ryP NGH6[pc{KGh? NE\2TYRUfXCycnXzd4lwdiCxZjDyVm5CKHO7boTo[ZNqew>? M3HYNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEG0O|c2Lz5{NUCxOFc4PTxxYU6=
Microglia NWHTRo1TTnWwY4Tpc44hSXO|YYm= MYi1JO69VQ>? NXSzR2NFOTBiaB?= M4HlXWROW09? M1ryUmRm[3KnYYPlJI9nKFSQRnGgd4VkemW2aX;uJIZzd21iTGDTMZN1cW23bHH0[YQhKHBzMUFOuGQ6OTCDL1S5NVBCKG2rY4Lv[4xq[Q>? NGrFe4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[yOVY5PCd-MkS2NlU3QDR:L3G+
Primary CLL cell MnnKSpVv[3Srb36gRZN{[Xl? NGC1VlYyKM7:TR?= MWWxOUBucW5? MWTEUXNQ M{CwW2Jtd2OtczDCR3IucW6mdXPl[EBNS1BzIIPldolv\S13IHHjeIl3[XSrb36= MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDByOUKzN{c,OjRyMEmyN|M9N2F-
JEKO-1 MoXlSpVv[3Srb36gRZN{[Xl? M2nnTlEh|ryP M2\JcFczKGh? M1TxTmlvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbjDpckBK\01vc4TpcZVt[XSnZDDKSWtQNTF? NUXVcJZLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzOFE2PDFpPkKzN|QyPTRzPD;hQi=>
Granta-519 NHu0dWVHfW6ldHnvckBCe3OjeR?= NFnE[JUyKM7:TR?= NUjQXoVCOiCq Mo\kTY5pcWKrdHnvckBw\iCDa4SoeFMxQClicHjvd5Bpd3K7bHH0bY9v NYHDS4dlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzOFE2PDFpPkKzN|QyPTRzPD;hQi=>
Granta-519 NUjS[IRTTnWwY4Tpc44hSXO|YYm= MnXoNUDPxE1? NHPxdpUzKGh? NW\MPHl7UW6qaXLpeIlwdiCxZjDBb5QpezR5MzmgdIhwe3Cqb4L5cIF1cW:w Mn;DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|NEG1OFEoRjJ|M{SxOVQyRC:jPh?=
JEKO-1 MnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L5elExKM7:TR?= M3LjdFczKGh? NGPs[4NKdmirYnn0bY9vKG:oIIDyc4xq\mW{YYTpc44he2yrZ3j0cJk> M3f5T|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{SxOVQyLz5{M{O0NVU1OTxxYU6=
JEKO-1 M{fCfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX[1JO69VQ>? MXe3NkBp NEH5Vmlld2W|IH7veEBqdmS3Y3WgZ4VtdCCleXPs[UBienKnc4Sgc5Ih[XCxcITvd4l{ NEDaV4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[3OlIzOCd-MkO2O|YzOjB:L3G+
MAVER-1 M4PlTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\MOUDPxE1? NHnubGQ4OiCq M2nofIRw\XNibn;0JIlv\HWlZTDj[YxtKGO7Y3zlJIFzemW|dDDvdkBieG:ydH;zbZM> NH3wVnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[3OlIzOCd-MkO2O|YzOjB:L3G+
MINO MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWS1JO69VQ>? MYG3NkBp MYTkc4V{KG6xdDDpcoR2[2ViY3XscEBkgWOuZTDhdpJme3Rib4KgZZBweHSxc3nz M1fFe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|Nke2NlIxLz5{M{[3OlIzODxxYU6=
SP53 MnPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEKw[Y8xNjFizszN Mn;rO|IhcA>? MYnkc4V{KG6xdDDpcoR2[2ViY3XscEBkgWOuZTDhdpJme3Rib4KgZZBweHSxc3nz MoD0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4N{[yNlAoRjJ|Nke2NlIxRC:jPh?=
HH M{HBZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFS2OGwyOCEQvF2= NYTBc4pDPzJiaB?= NHzqPIFFVVOR NWLEempHUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDzcIlocHSueR?= Mln4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6MEG5OVkoRjJ{OECxPVU6RC:jPh?=
Myla NUDtbJhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTUS5F6OTBizszN M2jiUVczKGh? MkW1SG1UVw>? M1zYUIRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYO= Mom1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6MEG5OVkoRjJ{OECxPVU6RC:jPh?=
SR786 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUCxNEDPxE1? MYO3NkBp MXjEUXNQ NEDI[XJld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nz MoPlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6MEG5OVkoRjJ{OECxPVU6RC:jPh?=
HuT78 M1rvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nsVlExKM7:TR?= NFzTbnQ4OiCq M4HSO2ROW09? NFrje2Vld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nz M3jETVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OECxPVU6Lz5{MkiwNVk2QTxxYU6=
MJ M4nqdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHYcWgyOCEQvF2= M1XkblczKGh? MWjEUXNQ NIDiU3lld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nz M1XKbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OECxPVU6Lz5{MkiwNVk2QTxxYU6=
DERL7 MlvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;CUHVNOTBizszN M4\VSVczKGh? M3:0WWROW09? NH7xZ29ld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nz M2XWZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OECxPVU6Lz5{MkiwNVk2QTxxYU6=
L1236 M{fQW2Z2dmO2aX;uJGF{e2G7 MYKxNEDPxE1? NFHMSHYzKGh? MXPJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25? NVX0SVI6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNVA5PzdpPkKyNlExQDd5PD;hQi=>
L428 MnHiSpVv[3Srb36gRZN{[Xl? NVSy[2FmOTBizszN M1Gwc|IhcA>? NIXySpJKdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36= NHzoUZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNFg4Pyd-MkKyNVA5Pzd:L3G+
L591 NVjCWGczTnWwY4Tpc44hSXO|YYm= MnGwNVAh|ryP M1fqeFIhcA>? MWfJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25? NXLrWnI{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNVA5PzdpPkKyNlExQDd5PD;hQi=>
KMH-2 NWP4b2xpTnWwY4Tpc44hSXO|YYm= MUmxNEDPxE1? M{\pZlIhcA>? NV\HeFVHUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;u NITmbVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNFg4Pyd-MkKyNVA5Pzd:L3G+
L1236 MnfYSpVv[3Srb36gRZN{[Xl? M3;MNlUh|ryP NXnmWo83OjRiaB?= MoDhRoxw[2u|IIPlZ5JmfGmxbjDv[kB1cGViQ1PMOS=> NVrFdXpERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNVA5PzdpPkKyNlExQDd5PD;hQi=>
L591 MVnGeY5kfGmxbjDBd5NigQ>? MmHpOUDPxE1? NYix[3lJOjRiaB?= M37RdWJtd2OtczDz[YNz\XSrb36gc4YhfGinIFPDUFU> M4HsUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkGwPFc4Lz5{MkKxNFg4PzxxYU6=
L1236 M1PKemFxd3C2b4Ppd{BCe3OjeR?= NEHWbos2KM7:TR?= NW\lXoZVOjRiaB?= MUjJcoR2[3Srb36gc4Yh[XCxcITvd4l{ Ml\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MUC4O|coRjJ{MkGwPFc4RC:jPh?=
L591 NFnZfJBCeG:ydH;zbZMhSXO|YYm= NY\sVo5jPSEQvF2= MofHNlQhcA>? NVThR21{UW6mdXP0bY9vKG:oIHHwc5B1d3Orcx?= MlPGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MUC4O|coRjJ{MkGwPFc4RC:jPh?=
U-87MG M{DkUGZ2dmO2aX;uJGF{e2G7 NH7R[FMyODBibl2= MXOyOEBp NF\XPVdFVVOR Mk\zTY5pcWKrdHnvckBw\iBiY3XscEBucWe{YYTpc44> NWjudXlGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwO|k3ODlpPkKyNFc6PjB7PD;hQi=>
SW1783 M4jVPGZ2dmO2aX;uJGF{e2G7 MmTnNVAxKG6P MXKyOEBp NVXRdoVMTE2VTx?= NELiU3JKdmirYnn0bY9vKG:oIDDj[YxtKG2rZ4LheIlwdg>? NFzCb5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC3PVYxQSd-MkKwO|k3ODl:L3G+
U-87MG NHvPNoVHfW6ldHnvckBCe3OjeR?= MlH4OUDPxE1? NGfrO|kzPCCq NFLwS5JFVVOR NGrsNnhKdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36gd5Vje3SjboTpZYxtgQ>? MmnzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyN{m2NFkoRjJ{MEe5OlA6RC:jPh?=
SW1783 MnznSpVv[3Srb36gRZN{[Xl? NFftR|I2KM7:TR?= MV2yOEBp MkjMSG1UVw>? NV7EbFExUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;uJJN2[nO2YX70bYFtdHl? NWPrTYVJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwO|k3ODlpPkKyNFc6PjB7PD;hQi=>
U-373MG NIXkXVBHfW6ldHnvckBCe3OjeR?= MX61JO69VQ>? Mnf3NlQhcA>? NHzEZ3FFVVOR NUKxVlJkUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;uJJN2[nO2YX70bYFtdHl? NVO0OYRNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwO|k3ODlpPkKyNFc6PjB7PD;hQi=>
SK-MG3 NGnXVmJHfW6ldHnvckBCe3OjeR?= NEDINJY2KM7:TR?= MU[yOEBp NF;zUZVFVVOR MY\Jcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25ic4Xid5RidnSrYXzsfS=> MlzuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyN{m2NFkoRjJ{MEe5OlA6RC:jPh?=
SU-DHL-5 NEPOTphHfW6ldHnvckBCe3OjeR?= NHHkbJYyKM7:TR?= MVyyOEBp M1n5cmROW09? MmPSTY5lfWO2aX;uJI9nKGGyb4D0c5Nqew>? MmrHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB7NUm2NFYoRjJyOUW5OlA3RC:jPh?=
WSU-NHL MWDGeY5kfGmxbjDBd5NigQ>? NX\IXXBpOSEQvF2= MVOyOEBp NUW4[INXTE2VTx?= Mo\2TY5lfWO2aX;uJI9nKGGyb4D0c5Nqew>? NUDsOXFURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC5OVk3ODZpPkKwPVU6PjB4PD;hQi=>
CCRF-SB MmTKSpVv[3Srb36gRZN{[Xl? Ml3XNUDPxE1? Mo\tNlQhcA>? M2PicWROW09? Mmn1TY5lfWO2aX;uJI9nKGGyb4D0c5Nqew>? M32ybFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOUW5OlA3Lz5{MEm1PVYxPjxxYU6=
INA-6 MVzGeY5kfGmxbjDBd5NigQ>? Mnf3OUDPxE1? M2frTlYhcA>? NUXrT2IyUW6qaXLpeIlwdiCxZjDQTVNMN0GtdDDhcoQhTVKNIIDheIh4[Xl? M{nuUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUC1NVU5Lz5{MEWwOVE2QDxxYU6=
LB MYPGeY5kfGmxbjDBd5NigQ>? MnHWOUDPxE1? MV[2JIg> NEnDSVFKdmirYnn0bY9vKG:oIGDJOGswSWu2IHHu[EBGWkticHH0bJdigQ>? NVrkb|RvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC1NFUyPThpPkKwOVA2OTV6PD;hQi=>
B-cells M2nnemZ2dmO2aX;uJIF{e2G7 M3vO[WlvcGmkaYTpc44hd2ZiUFmzT4RmdHSjIHnuJGIu[2WubIOgZpkheHKxbHnm[ZJifGmxbjDhd5NigSxiSVO1NEA:KDBwMEC2NUDPxE1w M3fDS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUK0Olg5Lz5{MkmyOFY5QDxxYU6=
MOLM14 M1H3SmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NXy4N3Q2OyCmYYnz MYrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2RTF2xOEBk\WyuczDh[pRmeiB|IHThfZMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OCB;IEOuOkDPxE1w MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd5NEGyO{c,Ojd5N{SxNlc9N2F-
MV4-11 MUHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MX[zJIRigXN? MoS0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPVkStNVEh[2WubIOgZYZ1\XJiMzDkZZl{KGK7IFPlcIxVcXSncj3HcI8h[XO|YYmsJGlEPTBiPTC2MlMh|ryPLh?= NV3hcoVERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O|QyOjdpPkK3O|c1OTJ5PD;hQi=>
Jurkat M3XPcmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M1y2[FMh\GG7cx?= M3XzZ2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSoXyb4F1KGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDD[YxtXGm2ZYKtS4xwKGG|c3H5MEBKSzVyIE2gO{46KM7:TT6= NFHBfos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e3OFEzPyd-Mke3O|QyOjd:L3G+
Loucy NYPESG1bSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M2LVXlMh\GG7cx?= MVnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEyxdXP5JINmdGy|IHHmeIVzKDNiZHH5d{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDJR|UxKD1iOD60JO69VS5? MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd5NEGyO{c,Ojd5N{SxNlc9N2F-
MOLT4 NE\CZWVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MkKyN{Bl[Xm| NHv4O4dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUHQ1KGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDD[YxtXGm2ZYKtS4xwKGG|c3H5MEBKSzVyIE2gNVAvPiEQvF2u M2HaPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{e0NVI4Lz5{N{e3OFEzPzxxYU6=
insect cells M{XYc2Z2dmO2aX;uJIF{e2G7 MmexTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsJIxmdme2aDDIbZMufGGpZ3XkJHBKO0upYX3tZUBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzMEBKSzVyIE2gNE4xQDlizszNMi=> M2m5[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OES2OFUyLz5{N{i0OlQ2OTxxYU6=
SUDHL6 MnHjRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NYn0[FY5PzJiaILz NHT6eHZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPVSGhNPiClZXzsd{Bu\WG|dYLl[EBi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO|YYmsJGlEPTBiPTCwMlEyPzZizszNMi=> MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzh2NkS1NUc,Ojd6NE[0OVE9N2F-
insect cells MonZSpVv[3Srb36gZZN{[Xl? M4DC[mlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscEBt\W6pdHigTIl{NXSjZ3fl[EBRUTONYnX0ZUBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzMEBKSzVyIE2gNE42PjVizszNMi=> NH;KSFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{i0OlQ2OSd-Mke4OFY1PTF:L3G+
SU-DHL4 M1HXW2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 M3ThdlczKGi{cx?= Mn7ERY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVVT3ETGw1KGOnbHzzJI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IEGuOkDPxE1w MmewQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6NE[0OVEoRjJ5OES2OFUyRC:jPh?=
Pfeiffer NYHHbpg4SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M1iwT|czKGi{cx?= MVnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCoZXnm[oVzKGOnbHzzJI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IE[uPEDPxE1w M3;JS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OES2OFUyLz5{N{i0OlQ2OTxxYU6=
KARPAS422 NFP4d|NCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M1S4Z|czKGi{cx?= NHLKfmlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvBVnBCWzR{MjDj[YxteyCvZXHzeZJm\CCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUCgQUA5NjFizszNMi=> M3Lo[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OES2OFUyLz5{N{i0OlQ2OTxxYU6=
Sf21 Mn;USpVv[3Srb36gZZN{[Xl? M{m1S|MxKG2rboO= MX3Jcohq[mm2aX;uJI9nKE5vdHXycYlv[WxiSHnzOk11[WepZXSgdoVkd22kaX7hcpQh\nWubD3s[Y5ofGhiaIXtZY4hWEl|SzDwNVEx[mW2YT;1cpRi\2enZDDy[YNwdWKrbnHueEBnfWyuIHzlcod1cCCqdX3hckBxQDWjbIDoZUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgV4YzOSCrboPlZ5Qh[2WubIOgeZNqdmdiUFnQNk9CXFBiYYOgd5Vje3S{YYTlJIFnfGW{IEOwJI1qdnNiYomgWHIuTlKHVDDhd5NigSxiSVO1NEA:KDNwNzFOwG0v MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDFyNkm5NUc,OjhzME[5PVE9N2F-
Sf21 M3zFWmZ2dmO2aX;uJIF{e2G7 M1uw[FMxKG2rboO= MlrjTY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFjpd|YufGGpZ3XkJJJm[2:vYnnuZY51KG[3bHytcIVv\3SqIHj1cYFvKFCLM1ugdFEyOGKndHGveY51[WepZXSgdoVkd22kaX7hcpQh\nWubDDs[Y5ofGhiaIXtZY4heDh3YXzwbIEh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJHNnOjFiaX7z[YN1KGOnbHzzJJV{cW6pIGDJVFIwSVSSIHHzJJN2[nO2cnH0[UBi\nSncjCzNEBucW6|IHL5JHRTNU[URWSgZZN{[XluIFnDOVAhRSB|Lkeg{txONg>? NYXu[GNWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixNFY6QTFpPkK4NVA3QTlzPD;hQi=>
RPMI8266 NEHvRW1CdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MUS3NkBpenN? M17lZWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUmDNTVgzPjZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODB3NEmg{txONg>? NYTXfmlqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNlU3ODFpPkK4N|I2PjBzPD;hQi=>
Raji NIPVTJdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NWjUVFJwPzJiaILz NGCw[nJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGLhbokh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFA6QTVizszNMi=> MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN{NU[wNUc,Ojh|MkW2NFE9N2F-
KARPAS422 MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1O3dmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGtCWlCDU{SyNkBk\WyuczDifUBES0t6IHHzd4F6NCCJSUWwJF0hOC54ODFOwG0v NFG4NYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEizOVgxPSd-Mki4N|U5ODV:L3G+
Pfeiffer NXfRNGQ5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHrn[3VIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBR\mWrZn\ldkBk\WyuczDifUBES0t6IHHzd4F6NCCJSUWwJF0hOC55NDFOwG0v NFnzXHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEizOVgxPSd-Mki4N|U5ODV:L3G+
Saos-2 MXrxTHRUKGG|c3H5 MlHLdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?= MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-SH M1vqPJFJXFNiYYPzZZk> NI[yOJhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=> MnzxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R) M3;JZZFJXFNiYYPzZZk> NHr3SI1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTVegOlMhMDZvVFegVkkh[2WubIO= NFnwNHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 NIDwdVByUFSVIHHzd4F6 M4PEN5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO= NV\lfGlyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 M33rSpFJXFNiYYPzZZk> Mo\mdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh41 MWPxTHRUKGG|c3H5 Mn\GdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN? M1O1dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC M1zvRZFJXFNiYYPzZZk> NXPNN|BweUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM> MnPKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1 NWDmR41XeUiWUzDhd5NigQ>? NXvhR25oeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM> MkP6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
LAN-5 MoTjdWhVWyCjc4PhfS=> MYjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN? MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SUDHL6 MnzHRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NFvwSlc4OiCqcoO= M1LEeWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2XETGw3KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDDR2s5KGG|c3H5MEBKSzVyIE2gNE43PSEQvF2u M4[yV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUO0PVM3Lz5{OUWzOFk{PjxxYU6=
RPMI8226 NX[3WlVkSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MmrNO|IhcHK| M2j2UGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUmDNTVgzOjZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFUvPDlizszNMi=> M4f0SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUO0PVM3Lz5{OUWzOFk{PjxxYU6=
Raji M4TI[GFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NIHzZ2E4OiCqcoO= NX;1[XBCSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDSZYpqKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTC5Mlk2KM7:TT6= NHTq[W89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWzOFk{Pid-Mkm1N|Q6OzZ:L3G+
SU-DHL6 NVKwfZVtT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVvHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDTWU1FUEx4IHPlcIx{KGK7IFPlcIxVcXSncj3HcI8h[XO|YYmsJGdKPTBiPTCwMlA1OiEQvF2u NFT4UJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[wNVk6OSd-Mkm2NFE6QTF:L3G+
MOLM13 M1nrbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3nIOlczKGi{cx?= NXLYWGY5T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVU:OTUGzJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIx2dWmwZYPj[Y51KGG|c3H5MEBIUTVyIE2gNU44KM7:TT6= M{PaNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEWzO|IyLz5|MEC1N|czOTxxYU6=
MOLM14 MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHHn[Jg4OiCqcoO= NEXu[4dIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOV0yPMUSgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gcJVucW6nc3PlcpQh[XO|YYmsJGdKPTBiPTC2MlQh|ryPLh?= MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB3M{eyNUc,OzByNUO3NlE9N2F-
MOLM14 NVP1ZnloSW62aYT1cY9zKGG|c3H5 M{fuPVExOCCvZz;r[y=> NUDNNVh[OTRiZHH5dy=> M2\CbmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUG0yPCClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDueU9vfSCvb4Xz[UBie3Onc4Pl[EBieyC2dX3vdkBoem:5dHigbY5pcWKrdHnvckBifCBzMECgcYcwc2duIIDvJIFldWmwaYP0[ZJm\CCmYXnsfUB3cWFiZ3H2ZYdmKGSxc3XkJIZweiBzNDDkZZl{KGGwZDDt[YF{fXKnZDDkZYltgSCmdYLpcoch[2:vcH;1coQh\G:|aX7nJJJmdGG2aY\lJJRwKGOxboTyc4w> MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB3M{eyNUc,OzByNUO3NlE9N2F-
MOLM14 MmT1RY51cXS3bX;yJIF{e2G7 NHLaN|QyODBibXevb4c> NUXseW5sOTRiZHH5dy=> M3vieWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUG0yPCClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDueU9vfSCvb4Xz[UBie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gZZBweHSxc3nzJIF1KDFyMDDt[{9s\yxicH:gZYRucW6rc4TldoVlKGSjaXz5JJZq[SCpYY\h[4Uh\G:|ZXSg[o9zKDF2IHThfZMh[W6mIH3lZZN2emWmIHThbYx6KGS3cnnu[{Bkd22yb4Xu[EBld3OrbnegZpkhXFWQRVygZoF{\WRiYYPzZZk> M2nrdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEWzO|IyLz5|MEC1N|czOTxxYU6=
MOLM14 MYnBcpRqfHWvb4KgZZN{[Xl? MlrwNVAxKG2pL3vn NYjKTYZiOTRiZHH5dy=> M3vnWGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUG0yPCClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDueU9vfSCvb4Xz[UBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJR2dW:{IIDyc4xq\mW{YYTpc44hOTByIH3nM4toNCCybzDh[I1qdmm|dHXy[YQh\GGrbImgeoliKGejdnHn[UBld3OnZDDmc5IhOTRiZHH5d{BidmRibXXhd5Vz\WRiZHHpcJkh\HW{aX7nJINwdXCxdX7kJIRwe2mwZzDifUBMcS14NzDsZYJmdGyrbnegZoF{\WRiaX3teY5wcA>? MnrOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByNUO3NlEoRjNyMEWzO|IyRC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Akt(T308) / PDK1(S241) / GSK-3β(S9); 

PubMed: 27342398     


JeKo-1, Mino, and Granta 519 cells or cells from four different MCL patients were serum-starved for 1h and then treated with DMSO, or with 0.5, 1, or 3μM for 1h; the cells were then co-cultured with IgM (10ng/μL) for 15min before harvesting. Cell extracts were prepared, and 30μg (cell lines) or 50μg (primary cells) protein was loaded for immunoblot analyses. The effects of idelalisib on Akt (Thr308) and total Akt, PDK1 (Ser241) and total PDK1, GS3K-3β (Ser9) and total GSK-3β protein expression levels were detected in (A) JeKo-1, Mino and Granta 519 cells.

p-FoxO3a / FoxO3a; 

PubMed: 30224718     


HepG2 cells were treated with 5 μmol/L idelalisib for 24 h. Indicated protein expression was analyzed by western blotting and p-FoxO3a normalized to FoxO3a, p-AKT normalized to AKT. The data represent the mean ± SD of three independent experiments. **P < 0.01 (one-way ANOVA with Tukey’s post hoc test). 

Mcl-1 / Bcl-2 / Bid / Bcl-xl / Noxa / Bak / Bax ; 

PubMed: 30224718     


HepG2 cells were treated with 5 μmol/L idelalisib at indicated time points. The expression of indicated Bcl-2 family members was analyzed by western blotting and normalized to β-actin. The data represent the mean ± SD of three independent experiments. **P < 0.01 (one-way ANOVA with Tukey’s post hoc test).

Cleaved caspase 3 / Cleaved caspase 9; 

PubMed: 28008149     


HepG2 cells were treated with 5μmol/L idelalisib at indicated time point. Cleaved-caspase 3 and 9 were analyzed by western blotting.

p-AKT / AKT; 

PubMed: 28008149     


HCT116 cells were treated with 10 μmol/L idelalisib at indicated time point. Total AKT and p-AKT expression was analyzed Western blotting.

p-p65; 

PubMed: 28008149     


HCT116 cells were treated with 10 μmol/L idelalisib at indicated time point. p-p65 (S536) and p65 expression was analyzed by Western blotting.

Bim / Bcl-xl / Bid / Mcl-1; 

PubMed: 28008149     


HCT116 cells treated with 10 μmol/L idelalisib at indicated time point. The expression of indicated Bcl-2 family members was analyzed by Western blotting.

PUMA / p53 ; 

PubMed: 28008149     


Parental and p53-KD HCT116 cells were treated with 10 μmol/L idelalisib for 24 hours. PUMA expression was analyzed by Western blotting.

27342398 30224718 28008149
Growth inhibition assay
Cell viability; 

PubMed: 30224718     


The indicated cell lines were treated with increasing concentrations of idelalisib for 72 h. Cell viability was determined by MTS assay.

Cell viability; 

PubMed: 28008149     


Indicated cell lines were treated with different concentrations of idelalisib for 72 hours. Cell proliferation was determined by MTS assay. Results were expressed as means ± SD of three independent experiments.

30224718 28008149

Protocol

Kinase Assay:[2]
- Collapse

PI3K assay:

PI3K assay is preformed on whole-cell lysates from CLL or normal B cells. A PI3K ELISA assay is performed. Briefly, whole-cell extracts are added to a mixture of PI(4,5)P2 substrate and reaction buffer containing adenosine triphosphate (ATP) and allowed to incubate at room temperature. The reaction is stopped by adding PI(3,4,5)P3 detector mixed with EDTA (ethylenediaminetetraacetic acid) and allowed to incubate at room temperature for 1 hour. After this time, the mixture is transferred from each well to a PI3K ELISA plate and allowed to incubate 1 hour. Plates are washed and then incubated with secondary detector for 30 minutes. Plates are washed again, and 3,3′,5,5′-tetramethylbenzidine solution is added for 5 minutes at which time H2SO4 is added to stop all reactions. Plates are read at 450 nm on a Labsystems 96-well plate reader.
Cell Research:[2]
- Collapse
  • Cell lines: CLL B cells or healthy volunteer T cells or NK cells
  • Concentrations: 0.01-100 μM
  • Incubation Time: 48 hours
  • Method: MTT assays are performed to determine cytotoxicity. 1 × 105 cells are incubated with CAL-101. MTT reagent is then added, and plates are incubated for an additional 20 hours before washing with protamine sulfate in phosphate-buffered saline. DMSO is added, and absorbance is measured by spectrophotometry at 540 nm in a Labsystems plate reader. Cell viability is also measured at various time points with the use of annexin/PI flow cytometry. Data are analyzed. At least 104 cells are counted for each sample. Results are expressed as the percentage of total positive cells over untreated control. Experiments examining caspase-dependent apoptosis included the addition of 100 μM Z-VAD. Experiments examining survival signals include the addition of 1 μg/mL CD40L, 800 U/mL IL-4, 50 ng/mL BAFF, 20 ng/mL TNF-α, or coculturing on fibronectin or stromal (HS-5 cell line) coated plates. Stromal coculture is done by plating a 75-cm2 flask (80%-100% confluent) per 6-well plate 24 hours before the addition of CLL cells.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 83 mg/mL warmed (199.79 mM)
Ethanol 23 mg/mL (55.36 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+20%PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 415.42
Formula

C22H18FN7O

CAS No. 870281-82-6
Storage powder
in solvent
Synonyms N/A
Smiles CCC(C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03582098 Completed Drug: Idelalisib|Drug: Rituximab Chronic Lymphocytic Leukaemia Gilead Sciences September 12 2018 --
NCT03151057 Active not recruiting Drug: Idelalisib 100 MG|Drug: Placebo Oral Tablet B Cells-Tumors|B Cell Chronic Lymphocytic Leukemia|Follicular Lymphoma|Mantle Cell Lymphoma|Large B-Cell Diffuse Lymphoma of Bone (Diagnosis) Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Gilead Sciences July 31 2018 Phase 1
NCT03568929 Active not recruiting Drug: Idelalisib Follicular Non-Hodgkin''s Lymphoma Refractory Gilead Sciences May 25 2018 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the recommended dose of CAL-101 and the route of administration for mouse studies?

  • Answer:

    According to the following paper, S2226 can be used by I.V. administration at the concentration of 40 mg/kg. https://www.ncbi.nlm.nih.gov/pubmed/24625684

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Idelalisib (CAL-101, GS-1101) | Idelalisib (CAL-101, GS-1101) supplier | purchase Idelalisib (CAL-101, GS-1101) | Idelalisib (CAL-101, GS-1101) cost | Idelalisib (CAL-101, GS-1101) manufacturer | order Idelalisib (CAL-101, GS-1101) | Idelalisib (CAL-101, GS-1101) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID